Business & Regulation
UK’s NICE recommends AbbVie’s Aquipta to treat migraines
The oral drug, which gained UK approval in September 2023, is used for the prevention of both chronic and episodic migraines.
The oral drug, which gained UK approval in September 2023, is used for the prevention of both chronic and episodic migraines.